Combining paclitaxel with repurposing drugs improve ovarian cancer management

Authors

  • Mariana Nunes Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal. Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal.
  • Catarina Brandão Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal. Faculty of Medicine, University of Porto (FMUP), 4200-319 Porto, Portugal.
  • Sara Ricardo Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal. Faculty of Medicine, University of Porto (FMUP), 4200-319 Porto, Portugal. TOXRUN – Toxicology Research Unit, University Institute of Health Sciences, CESPU, CRL, 4585-116 Gandra, Portugal.

DOI:

https://doi.org/10.51126/revsalus.v4iSup.301

Keywords:

chemoresistance, combination therapy, drug repurposing, ovarian cancer, paclitaxel

Downloads

Download data is not yet available.

Downloads

Published

2022-04-06

Conference Proceedings Volume

Vol. 4 No. Sup (2022): Suplemento da RevSALUS - Revista Científica Internacional da RACS

Section

Posters

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite

Combining paclitaxel with repurposing drugs improve ovarian cancer management. (2022). RevSALUS - International Scientific Journal of the Academic Network of Health Sciences of Lusophone, 4(Sup), 79. https://doi.org/10.51126/revsalus.v4iSup.301